Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

The PDGFRβ-AKT pathway contributes to CDDP-acquired resistance in testicular germ cell tumors.

Juliachs M, Muñoz C, Moutinho CA, Vidal A, Condom E, Esteller M, Graupera M, Casanovas O, Germà JR, Villanueva A, Viñals F.

Clin Cancer Res. 2014 Feb 1;20(3):658-67. doi: 10.1158/1078-0432.CCR-13-1131. Epub 2013 Nov 25.

2.

Re: The PDGFRβ-AKT Pathway Contributes to CDDP-Acquired Resistance in Testicular Germ Cell Tumors.

Richie JP.

J Urol. 2015 Jul;194(1):117. doi: 10.1016/j.juro.2015.04.007. Epub 2015 Apr 8. No abstract available.

PMID:
26088228
3.

Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.

Castillo-Avila W, Piulats JM, Garcia Del Muro X, Vidal A, Condom E, Casanovas O, Mora J, Germà JR, Capellà G, Villanueva A, Viñals F.

Clin Cancer Res. 2009 May 15;15(10):3384-95. doi: 10.1158/1078-0432.CCR-08-2170. Epub 2009 May 5.

4.

Effectivity of pazopanib treatment in orthotopic models of human testicular germ cell tumors.

Juliachs M, Vidal A, Del Muro XG, Piulats JM, Condom E, Casanovas O, Graupera M, Germà JR, Villanueva A, Viñals F.

BMC Cancer. 2013 Aug 10;13:382. doi: 10.1186/1471-2407-13-382.

5.

Cisplatin-induced apoptosis in human malignant testicular germ cell lines depends on MEK/ERK activation.

Schweyer S, Soruri A, Meschter O, Heintze A, Zschunke F, Miosge N, Thelen P, Schlott T, Radzun HJ, Fayyazi A.

Br J Cancer. 2004 Aug 2;91(3):589-98.

6.

Par-4 downregulation confers cisplatin resistance in pancreatic cancer cells via PI3K/Akt pathway-dependent EMT.

Tan J, You Y, Xu T, Yu P, Wu D, Deng H, Zhang Y, Bie P.

Toxicol Lett. 2014 Jan 3;224(1):7-15. doi: 10.1016/j.toxlet.2013.10.008. Epub 2013 Oct 19.

PMID:
24144893
7.

Up-regulation of survivin by AKT and hypoxia-inducible factor 1α contributes to cisplatin resistance in gastric cancer.

Sun XP, Dong X, Lin L, Jiang X, Wei Z, Zhai B, Sun B, Zhang Q, Wang X, Jiang H, Krissansen GW, Qiao H, Sun X.

FEBS J. 2014 Jan;281(1):115-28. doi: 10.1111/febs.12577. Epub 2013 Nov 18.

8.

PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/ERK-dependent pathways.

Fu X, Feng J, Zeng D, Ding Y, Yu C, Yang B.

Biosci Rep. 2014 Apr 1;34(2). pii: e00094. Print 2014 Apr 1.

9.

The role of reactive oxygen species in cisplatin-induced apoptosis in human malignant testicular germ cell lines.

Schweyer S, Soruri A, Heintze A, Radzun HJ, Fayyazi A.

Int J Oncol. 2004 Dec;25(6):1671-6.

PMID:
15547704
10.

Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.

Li C, Ding H, Tian J, Wu L, Wang Y, Xing Y, Chen M.

Cell Physiol Biochem. 2016;39(1):242-52. doi: 10.1159/000445620. Epub 2016 Jun 24.

11.

HtrA1 downregulation induces cisplatin resistance in lung adenocarcinoma by promoting cancer stem cell-like properties.

Xu Y, Jiang Z, Zhang Z, Sun N, Zhang M, Xie J, Li T, Hou Y, Wu D.

J Cell Biochem. 2014 Jun;115(6):1112-21. doi: 10.1002/jcb.24751.

PMID:
24356998
12.

Activation of PI3K/AKT and MAPK pathway through a PDGFRβ-dependent feedback loop is involved in rapamycin resistance in hepatocellular carcinoma.

Li QL, Gu FM, Wang Z, Jiang JH, Yao LQ, Tan CJ, Huang XY, Ke AW, Dai Z, Fan J, Zhou J.

PLoS One. 2012;7(3):e33379. doi: 10.1371/journal.pone.0033379. Epub 2012 Mar 9.

13.

Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors.

Feldman DR, Iyer G, Van Alstine L, Patil S, Al-Ahmadie H, Reuter VE, Bosl GJ, Chaganti RS, Solit DB.

Clin Cancer Res. 2014 Jul 15;20(14):3712-20. doi: 10.1158/1078-0432.CCR-13-2868. Epub 2014 May 8.

14.

IGFBP-3 methylation-derived deficiency mediates the resistance to cisplatin through the activation of the IGFIR/Akt pathway in non-small cell lung cancer.

Cortés-Sempere M, de Miguel MP, Pernía O, Rodriguez C, de Castro Carpeño J, Nistal M, Conde E, López-Ríos F, Belda-Iniesta C, Perona R, Ibanez de Caceres I.

Oncogene. 2013 Mar 7;32(10):1274-83. doi: 10.1038/onc.2012.146. Epub 2012 Apr 30.

PMID:
22543588
15.

ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor.

Juliachs M, Castillo-Ávila W, Vidal A, Piulats JM, Garcia Del Muro X, Condom E, Hernández-Losa J, Teixidó C, Pandiella A, Graupera M, Casanovas O, Germà JR, Villanueva A, Viñals F.

Int J Cancer. 2013 Jul;133(1):235-46. doi: 10.1002/ijc.28009. Epub 2013 Feb 12.

16.

Loss of drug-induced activation of the CD95 apoptotic pathway in a cisplatin-resistant testicular germ cell tumor cell line.

Spierings DC, de Vries EG, Vellenga E, de Jong S.

Cell Death Differ. 2003 Jul;10(7):808-22.

17.
19.

The forkhead transcription factor FOXO1 mediates cisplatin resistance in gastric cancer cells by activating phosphoinositide 3-kinase/Akt pathway.

Park J, Ko YS, Yoon J, Kim MA, Park JW, Kim WH, Choi Y, Kim JH, Cheon Y, Lee BL.

Gastric Cancer. 2014;17(3):423-30. doi: 10.1007/s10120-013-0314-2. Epub 2013 Nov 8.

PMID:
24202965
20.

Loss of Oct-3/4 expression in embryonal carcinoma cells is associated with induction of cisplatin resistance.

Mueller T, Mueller LP, Luetzkendorf J, Voigt W, Simon H, Schmoll HJ.

Tumour Biol. 2006;27(2):71-83. Epub 2006 Mar 24.

PMID:
16557044

Supplemental Content

Support Center